ReviewJournal of the American College of Emergency Physicians open2020
COVID-19: A review of therapeutics under investigation.
Review in Journal of the American College of Emergency Physicians open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Metallo-antiviral aspirants:European journal of medicinal chemistry reports · 2023Review
- A Case Report of a Patient on Therapeutic Warfarin Who Died of COVID-19 Infection with a Sudden Rise in D-Dimer.Biomedicines · 2021Article
- Metal Complexes as Antiviral Agents for SARS-CoV-2.Chembiochem : a European journal of chemical biology · 2021Review
- Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization.Peptide science (Hoboken, N.J.) · 2021Article
- Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.International journal of molecular sciences · 2021Review
- Prone positioning for severe ARDS in a postpartum COVID-19 patient following caesarean section.BMJ case reports · 2021Article
- Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.Discoveries (Craiova, Romania) · 2020Review
- Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2.ACS pharmacology & translational science · 2020Article
- The use of ibuprofen to treat fever in COVID-19: A possible indirect association with worse outcome?Medical hypotheses · 2020Article
- Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.Life sciences · 2020Article
- Motivations for Social Distancing and App Use as Complementary Measures to Combat the COVID-19 Pandemic: Quantitative Survey Study.Journal of medical Internet research · 2020Article
- Virtual Remote Attending Supervision in an Academic Emergency Department During the COVID-19 Pandemic.AEM education and training · 2020Article
- COVID-19: A review of therapeutics under investigation.Journal of the American College of Emergency Physicians open · 2020Review
- Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials.SN comprehensive clinical medicine · 2020Review
- Pediatric Inflammatory Multisystem Syndrome and Rheumatic Diseases During SARS-CoV-2 Pandemic.Frontiers in pediatrics · 2020Review
- A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic.Frontiers in molecular biosciences · 2020Review
- Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.Frontiers in immunology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 outbreak has disrupted global health care networks and caused thousands of deaths and an international economic downturn. Multiple drugs are being used on patients with COVID-19 based on theoretical and in vitro therapeutic targets. Several of these therapies have been studied, but many have limited evidence behind their use, and clinical trials to evaluate their efficacy are either ongoing or have not yet begun. This review summarizes the existing evidence for medications currently under investigation for treatment of COVID-19, including remdesivir, chloroquine/hydroxychlorquine, convalescent plasma, lopinavir/ritonavir, IL-6 inhibitors, corticosteroids, and angiotensin-converting enzyme inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.